Estrogen receptor ligands, compositions and methods related thereto

Patent metadata

Field	Value
Publication number	US-10980767-B2
Application number	US-201716331670-A
Country	US
Kind code	B2
Filing date	Sep 8, 2017
Priority date	Sep 9, 2016
Publication date	Apr 20, 2021
Grant date	Apr 20, 2021

Abstract

Provided are compounds and methods for treating neurodegenerative diseases and conditions, such as multiple sclerosis, using an estrogen receptor-β ligand (ERβ ligand).

First claim

The invention claimed is:

1. A method of treating multiple sclerosis, comprising orally administering an ERβ ligand to a subject in need thereof wherein the ERβ ligand is a compound of Formula (I)

wherein
R 1 and R 2 are each independently —C(O)—R 3 ; and
each R 3 is independently selected from alkyl, alkoxy, alkoxyalkyl, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl.

2. The method of claim 1 , wherein R 3 is selected from alkyl, aryl and aralkyl.

3. The method of claim 2 , wherein R 3 is selected from methyl, ethyl, isopropyl, t-butyl, phenyl and benzyl.

4. The method of claim 1 , wherein the carbon bearing the CN substituent is in the R-configuration or the S-configuration.

5. The method of claim 1 , wherein the ERβ ligand is Compound 1:

6. The method of claim 1 , wherein the ERβ ligand is selected from:

7. The method of claim 1 , wherein the multiple sclerosis is relapsing-remitting multiple sclerosis.

8. The method of claim 1 , wherein the multiple sclerosis is secondary-progressive multiple sclerosis.

9. The method of claim 1 , wherein the multiple sclerosis is primary-progressive multiple sclerosis.

10. The method of claim 1 , wherein the multiple sclerosis is progressive-relapsing multiple sclerosis.

11. The method of claim 1 , wherein the multiple sclerosis is clinically isolated syndrome (CIS).

12. The method of claim 1 , wherein the ERβ ligand is administered orally.

13. The method of claim 1 , wherein the subject is not being treated with an immunotherapeutic agent.

14. The method of claim 1 , further comprising conjointly administering to the subject an immunotherapeutic agent.

15. The method of claim 14 , wherein treatment with the immunotherapeutic agent is initiated at the same time or about the same time as initiation of treatment with the ERβ ligand.

16. The method of claim 14 , wherein the immunotherapeutic agent is selected from interferon-beta 1a, interferon-beta 1b, glatiramer acetate, natalizumab, mitoxantrone, fingolimod, teriflunomide, dimethyl fumarate, mycophenolate mofetil, paclitaxel, cyclosporine, corticosteroids, azathioprine, cyclophosphamide, methotrexate, cladribine, 4-aminopyridine, and tizanidine.

17. The method of claim 14 , wherein the amount of the immunotherapeutic agent administered in combination with the ERβ ligand is less than a therapeutically effective amount when the immunotherapeutic agent is administered alone.

18. The method of claim 1 , wherein the ERβ ligand is administered at a dose of about 5 mg to about 120 mg per day.

19. The method of claim 14 , wherein the immunotherapeutic agent is glatiramer acetate.

Assignees

• Univ California

Inventors

• Jung Michael E
• Voskuhl Rhonda R

Classifications

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K31/277 Primary

  having a ring, e.g. verapamil · CPC title

• A61P25/14

  for treating abnormal movements, e.g. chorea, dyskinesia · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title